Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Stoke Therapeutics (STOK) Net Income towards Common Stockholders (2022 - 2025)

Stoke Therapeutics has reported Net Income towards Common Stockholders over the past 4 years, most recently at -$57.8 million for Q4 2025.

  • For Q4 2025, Net Income towards Common Stockholders fell 441.27% year-over-year to -$57.8 million; the TTM value through Dec 2025 reached -$6.8 million, up 92.4%, while the annual FY2025 figure was -$6.8 million, 92.3% up from the prior year.
  • Net Income towards Common Stockholders for Q4 2025 was -$57.8 million at Stoke Therapeutics, down from -$38.3 million in the prior quarter.
  • Over five years, Net Income towards Common Stockholders peaked at $112.9 million in Q1 2025 and troughed at -$57.8 million in Q4 2025.
  • A 4-year average of -$18.9 million and a median of -$25.7 million in 2022 define the central range for Net Income towards Common Stockholders.
  • On a YoY basis, Net Income towards Common Stockholders climbed as much as 527.99% in 2025 and fell as far as 441.27% in 2025.
  • Year by year, Net Income towards Common Stockholders stood at -$25.7 million in 2022, then fell by 5.07% to -$27.0 million in 2023, then skyrocketed by 60.43% to -$10.7 million in 2024, then plummeted by 441.27% to -$57.8 million in 2025.
  • Business Quant data shows Net Income towards Common Stockholders for STOK at -$57.8 million in Q4 2025, -$38.3 million in Q3 2025, and -$23.5 million in Q2 2025.